Zaremba Amy Rabourn's most recent trade in Opus Genetics Inc. was a trade of 39,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Opus Genetics Inc. | Rabourn Amy Zaremba | SVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 39,500 | 39,500 | - | - | Employee Stock Option (right to buy) | |
| Opus Genetics Inc. | Rabourn Amy Zaremba | SVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 39,500 | 113,968 | - | 0 | Common Stock | |
| Opus Genetics Inc. | Rabourn Amy Zaremba | SVP of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. | 04 Feb 2025 | 8,190 | 74,468 | - | 1.1 | 9,337 | Common Stock |
| Opus Genetics Inc. | Zaremba Amy Rabourn | SVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Opus Genetics Inc. | Rabourn Zaremba Amy | SVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 40,000 | 82,658 | - | 0 | Common Stock | |
| Opus Genetics Inc. | Amy Zaremba Rabourn | SVP of Finance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.27 per share. | 10 Jan 2024 | 3,950 | 42,658 | - | 3.3 | 12,897 | Common Stock |
| Opus Genetics Inc. | Rabourn Amy Zaremba | SVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2023 | 69,912 | 69,912 | - | - | Employee Stock Option (right to buy) | |
| Opus Genetics Inc. | Rabourn Amy Zaremba | SVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2023 | 46,608 | 46,608 | - | 0 | Common Stock | |
| Opus Genetics Inc. | Rabourn Amy Zaremba | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Opus Genetics Inc. | Rabourn Amy Zaremba | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2020 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) |